The false promise of regenerative medicine

摘要

Over nearly two decades now, I've followed the progress of "regenerative medicine"—mostly stem-cell research-through phase 1 studies, most of them featured in the Lancet. The yield has been spectacularly low. And now comes a Lancet commissioned article beginning: "In this Commission, we argue that a combination of poor quality science, unclear funding models, unrealistic hopes, and unscrupulous private clinics threatens regenerative medicine's social licence to operate."